245 related articles for article (PubMed ID: 29246496)
1. miRNAs as Biomarkers for Predicting the Progression of Ductal Carcinoma in Situ.
Hannafon BN; Ding WQ
Am J Pathol; 2018 Mar; 188(3):542-549. PubMed ID: 29246496
[TBL] [Abstract][Full Text] [Related]
2. Role of deregulated microRNAs in breast cancer progression using FFPE tissue.
Chen L; Li Y; Fu Y; Peng J; Mo MH; Stamatakos M; Teal CB; Brem RF; Stojadinovic A; Grinkemeyer M; McCaffrey TA; Man YG; Fu SW
PLoS One; 2013; 8(1):e54213. PubMed ID: 23372687
[TBL] [Abstract][Full Text] [Related]
3. Functional Role of miRNAs in the Progression of Breast Ductal Carcinoma in Situ.
Hannafon BN; Ding WQ
Am J Pathol; 2019 May; 189(5):966-974. PubMed ID: 30273605
[TBL] [Abstract][Full Text] [Related]
4. Identifying progression predictors of breast ductal carcinoma in situ.
Yeong J; Thike AA; Tan PH; Iqbal J
J Clin Pathol; 2017 Feb; 70(2):102-108. PubMed ID: 27864452
[TBL] [Abstract][Full Text] [Related]
5. Ectopic expression of PLC-β2 in non-invasive breast tumor cells plays a protective role against malignant progression and is correlated with the deregulation of miR-146a.
Bertagnolo V; Grassilli S; Volinia S; Al-Qassab Y; Brugnoli F; Vezzali F; Lambertini E; Palomba M; Piubello Q; Orvieto E; Natali C; Piva R; Croce CM; Capitani S
Mol Carcinog; 2019 May; 58(5):708-721. PubMed ID: 30582225
[TBL] [Abstract][Full Text] [Related]
6. Ductal carcinoma in situ of the breast: the importance of morphologic and molecular interactions.
Mardekian SK; Bombonati A; Palazzo JP
Hum Pathol; 2016 Mar; 49():114-23. PubMed ID: 26826418
[TBL] [Abstract][Full Text] [Related]
7. Loss of FAT1 during the progression from DCIS to IDC and predict poor clinical outcome in breast cancer.
Wang L; Lyu S; Wang S; Shen H; Niu F; Liu X; Liu J; Niu Y
Exp Mol Pathol; 2016 Feb; 100(1):177-83. PubMed ID: 26721716
[TBL] [Abstract][Full Text] [Related]
8. Gene expression profiling of tumour epithelial and stromal compartments during breast cancer progression.
Vargas AC; McCart Reed AE; Waddell N; Lane A; Reid LE; Smart CE; Cocciardi S; da Silva L; Song S; Chenevix-Trench G; Simpson PT; Lakhani SR
Breast Cancer Res Treat; 2012 Aug; 135(1):153-65. PubMed ID: 22718308
[TBL] [Abstract][Full Text] [Related]
9. Progression-specific genes identified in microdissected formalin-fixed and paraffin-embedded tissue containing matched ductal carcinoma in situ and invasive ductal breast cancers.
Schultz S; Bartsch H; Sotlar K; Petat-Dutter K; Bonin M; Kahlert S; Harbeck N; Vogel U; Seeger H; Fehm T; Neubauer HJ
BMC Med Genomics; 2018 Sep; 11(1):80. PubMed ID: 30236106
[TBL] [Abstract][Full Text] [Related]
10. Comparison of HER2 amplification status among breast cancer subgroups offers new insights in pathways of breast cancer progression.
Lambein K; Van Bockstal M; Vandemaele L; Van den Broecke R; Cocquyt V; Geenen S; Denys H; Libbrecht L
Virchows Arch; 2017 Nov; 471(5):575-587. PubMed ID: 28567637
[TBL] [Abstract][Full Text] [Related]
11. Cis-acting super-enhancer lncRNAs as biomarkers to early-stage breast cancer.
Ropri AS; DeVaux RS; Eng J; Chittur SV; Herschkowitz JI
Breast Cancer Res; 2021 Oct; 23(1):101. PubMed ID: 34717732
[TBL] [Abstract][Full Text] [Related]
12. Profiling differential microRNA expression between in situ, infiltrative and lympho-vascular space invasive breast cancer: a pilot study.
Soon PS; Provan PJ; Kim E; Pathmanathan N; Graham D; Clarke CL; Balleine RL
Clin Exp Metastasis; 2018 Feb; 35(1-2):3-13. PubMed ID: 29214365
[TBL] [Abstract][Full Text] [Related]
13. Genomic and mutational profiling of ductal carcinomas in situ and matched adjacent invasive breast cancers reveals intra-tumour genetic heterogeneity and clonal selection.
Hernandez L; Wilkerson PM; Lambros MB; Campion-Flora A; Rodrigues DN; Gauthier A; Cabral C; Pawar V; Mackay A; A'Hern R; Marchiò C; Palacios J; Natrajan R; Weigelt B; Reis-Filho JS
J Pathol; 2012 May; 227(1):42-52. PubMed ID: 22252965
[TBL] [Abstract][Full Text] [Related]
14. Analysis of stromal signatures in the tumor microenvironment of ductal carcinoma in situ.
Sharma M; Beck AH; Webster JA; Espinosa I; Montgomery K; Varma S; van de Rijn M; Jensen KC; West RB
Breast Cancer Res Treat; 2010 Sep; 123(2):397-404. PubMed ID: 19949854
[TBL] [Abstract][Full Text] [Related]
15. Subtype-specific micro-RNA expression signatures in breast cancer progression.
Haakensen VD; Nygaard V; Greger L; Aure MR; Fromm B; Bukholm IR; Lüders T; Chin SF; Git A; Caldas C; Kristensen VN; Brazma A; Børresen-Dale AL; Hovig E; Helland Å
Int J Cancer; 2016 Sep; 139(5):1117-28. PubMed ID: 27082076
[TBL] [Abstract][Full Text] [Related]
16. Validation of an oligo-gene signature for the prognostic stratification of ductal carcinoma in situ (DCIS).
Geradts J; Groth J; Wu Y; Jin G
Breast Cancer Res Treat; 2016 Jun; 157(3):447-59. PubMed ID: 27250000
[TBL] [Abstract][Full Text] [Related]
17. Tumor-associated myoepithelial cells promote the invasive progression of ductal carcinoma
Lo PK; Zhang Y; Yao Y; Wolfson B; Yu J; Han SY; Duru N; Zhou Q
J Biol Chem; 2017 Jul; 292(27):11466-11484. PubMed ID: 28512126
[TBL] [Abstract][Full Text] [Related]
18. Single-cell genetic analysis of ductal carcinoma in situ and invasive breast cancer reveals enormous tumor heterogeneity yet conserved genomic imbalances and gain of MYC during progression.
Heselmeyer-Haddad K; Berroa Garcia LY; Bradley A; Ortiz-Melendez C; Lee WJ; Christensen R; Prindiville SA; Calzone KA; Soballe PW; Hu Y; Chowdhury SA; Schwartz R; Schäffer AA; Ried T
Am J Pathol; 2012 Nov; 181(5):1807-22. PubMed ID: 23062488
[TBL] [Abstract][Full Text] [Related]
19. Expression of microRNA and their gene targets are dysregulated in preinvasive breast cancer.
Hannafon BN; Sebastiani P; de las Morenas A; Lu J; Rosenberg CL
Breast Cancer Res; 2011 Mar; 13(2):R24. PubMed ID: 21375733
[TBL] [Abstract][Full Text] [Related]
20. [Expression of fatty acid synthase and its association with HER2 in invasive ductal carcinoma of breast].
Yang M; Xu SP; Ao QL
Zhonghua Bing Li Xue Za Zhi; 2013 Apr; 42(4):257-61. PubMed ID: 23928534
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
